The global clinical trial landscape of PD-1-containing bispecific antibodies for gastric cancer: current status and future directions of targeting immune tolerance - Takeaways - MDSpire

The global clinical trial landscape of PD-1-containing bispecific antibodies for gastric cancer: current status and future directions of targeting immune tolerance

  • By

  • Ziyue Sha

  • Zhengzheng Ji

  • Lanqing Zhao

  • Song Wang

  • Zhanjun Guo

  • June 22, 2026

  • 0 min

Share

  • 1

    Gastric cancer is a leading cause of cancer-related death, with PD-1 monotherapy providing limited clinical benefit due to immune tolerance.

  • 2

    A total of 121 interventional clinical trials for PD-1-targeting bispecific antibodies in gastric cancer were identified, with continuous growth from 2017 to 2025.

  • 3

    Phase II trials represented the largest segment of the clinical trial landscape, focusing on safety and preliminary efficacy.

  • 4

    CTLA-4 was the most common non-PD-1 co-target in trials, with combination therapy primarily involving chemotherapy.

  • 5

    Most trials were conducted in China, indicating a significant geographical concentration in the development of PD-1 bispecific antibodies.

Original Source(s)

The global clinical trial landscape of PD-1-containing bispecific antibodies for gastric cancer: current status and future directions of targeting immune tolerance

  • by Ziyue Sha, Zhengzheng Ji, Lanqing Zhao, Song Wang, Zhanjun Guo

  • June 22, 2026

Related Content

Association between HPV-16 and HPV-18 viral loads and severity of cervical pre-invasive lesions in women with and without HIV in Botswana

Associations between psychological distress and thyroid cancer, and the mediating role of lifestyle and metabolism: a cohort study from the UK Biobank

Correction: Hospital-based patterns of esophageal and gastric cancer cases at a major tertiary referral center in Kabul, Afghanistan: a retrospective case series